As a result of the supply disruption of EGRIFTA SV during the first quarter of 2025 described above resulting in a one-time loss of 6 to 7 weeks of sales, and taking into account the approval of EGRIFTA WR, the company estimate FY2025 revenue to be in the range of $80 million to $83 million while we anticipate Adjusted EBITDA, a non-IFRS measure, to be between $10 and $12 million for the same period.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on THTX:
- Theratechnologies Gains FDA Approval for EGRIFTA SV Distribution
- Theratechnologies receives FDA approval of PAS for EGRIFTA SV sBLA
- THTX Earnings this Week: How Will it Perform?
- Theratechnologies Gains FDA Approval for New Tesamorelin Formulation
- Theratechnologies Gains FDA Nod for Enhanced HIV Treatment